Physician Assistant · New York, NY
NPI
1760537229
Since 2007
Specialty
Physician Assistant
Code 363A00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
520 E 70th St, Starr 341
New York, NY, 10021
Phone (646) 962-2700
Groups this clinician bills Medicare through
Medicare paid, 2024
$13K
131 services
Medicare patients, 2024
72
Average age 77
Drug cost, 2024
$6.6M
857 prescriptions
Company payments, 2025
$24K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Natalie Tafel was code 99215 (office e&m - established), 95 times for 48 patients. In total Natalie Tafel billed 131 services in 3 codes, and Medicare paid $13K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 95 | 48 | $115.38 | $11K |
| 38222 Other Organ Systems | Facility | 35 | 32 | $51.86 | $1,815 |
By year: 2022 $6,235 for 91 services; 2023 $7,337 for 92 services; 2024 $13K for 131 services.
Medicare prescription drug claims, 2024
In 2024, the drug Natalie Tafel prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 68 prescriptions and refills. In total Natalie Tafel wrote 857 Medicare prescriptions that cost $6.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 68 | 68 | 12 | $1.2M |
| Valacyclovir Valacyclovir Hcl | 54 | 76 | 21 | $849 |
| Hydroxyurea Generic | 47 | 71 | 17 | $1,097 |
| Venclexta Venetoclax | 44 | 46 | Under 11 | $427K |
| Prednisone Generic | 35 | 49 | Under 11 | $326 |
| Inqovi Decitabine/Cedazuridine | 34 | 34 | Under 11 | $259K |
| Scemblix Asciminib Hydrochloride | 32 | 32 | Under 11 | $678K |
| Allopurinol Generic | 31 | 48 | 11 | $349 |
| Zolpidem Tartrate Generic | 27 | 27 | Under 11 | $316 |
| Tibsovo Ivosidenib | 26 | 26 | Under 11 | $861K |
| Ojjaara Momelotinib Dihydrochloride | 22 | 22 | Under 11 | $610K |
| Reblozyl Luspatercept-Aamt | 21 | 21 | Under 11 | $205K |
| Gleevec Imatinib Mesylate | 18 | 18 | Under 11 | $169K |
| Mirtazapine Generic | 18 | 24 | Under 11 | $118 |
| Iclusig Ponatinib Hcl | 17 | 17 | Under 11 | $345K |
Brand drugs: 392 claims; generic drugs: 465 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Natalie Tafel $24K ($24K in general payments such as food, travel and fees) from 15 companies. The largest payer was Rigel Pharmaceuticals, Inc. with $17K.
| Company | Payments | Amount |
|---|---|---|
| Rigel Pharmaceuticals, Inc. RIGL | 21 | $17K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 6 | $2,946 |
| Amgen Inc. AMGN | 5 | $2,187 |
| Servier Pharmaceuticals LLC | 5 | $783 |
| Geron Corporation GERN | 1 | $513 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $275 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $217 |
| Sobi, Inc SOBI.ST | 3 | $79.32 |
| Azurity Pharmaceuticals, Inc. | 2 | $60.82 |
| Astellas Pharma US Inc 4503.T | 2 | $55.96 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.